Evaluation of ranibizumab-induced changes in high- resolution optical coherence tomographic retinal morphology and their impact on visual function

Christopher G. Kiss, Wolfgang Geitzenauer, Christian Simader, Giovanni Gregori, Ursula Schmidt-Erfurth

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

PURPOSE. To evaluate the effects of intravitreal ranibizumab on retinal function and morphology and to identify a correlation between anatomy and function by using spectral domain optical coherence tomography (SDOCT). METHODS. Twenty-three patients affected by neovascular AMD received three injections of ranibizumab in three consecutive months and were monitored by assessment of best corrected visual acuity (BCVA), central retinal sensitivity (CRS) and morphologic changes at the level of the retina and the retinal pigment epithelium (RPE). The morphologic changes, identified by SDOCT segmentation, were mean retinal thickness (MRT), central retinal thickness (CRT), and the pathologic area (lesion area) of the RPE. RESULTS. BCVA increased from a mean 60.1 ± 8.7 letters at baseline to 67.0 ± 10.9 at month 3 (P = 0.0003). The CRS at the 0° position increased from 2.8 ± 3.1 dB at baseline to 4.0 ± 5.7 at week 1, remaining stable until month 3. Absolute scotoma size decreased continuously from baseline to month 3, in a mean of 5.3 ± 5.8 to 3.6 ± 4.0 test point locations. By SDOCT, MRT decreased from 308.6 ± 25.9 m at baseline to 268.4 ± 22.4 m at month 3 (P = 0.0001). CRT was 365.8 ± 84.9 and 254.9 ± 95.1 μm at month 3 (P = 0.0002). The mean RPE lesion area was 6.0 ± 3.0 mm2 at baseline, which decreased to 5.0 ± 3.1 mm2 at month 3 (P = 0.115). The only significant correlation was identified between the lesion area and CRS. CONCLUSIONS. In ranibizumab therapy, the condition of the RPE lesion may be more relevant for visual function than the usual OCT parameters, retinal thickness.

Original languageEnglish
Pages (from-to)2376-2383
Number of pages8
JournalInvestigative Ophthalmology and Visual Science
Volume50
Issue number5
DOIs
StatePublished - Dec 1 2009

Fingerprint

Retinal Pigment Epithelium
Optical Coherence Tomography
Visual Acuity
Scotoma
Retina
Anatomy
Injections
Ranibizumab
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience
  • Medicine(all)

Cite this

Evaluation of ranibizumab-induced changes in high- resolution optical coherence tomographic retinal morphology and their impact on visual function. / Kiss, Christopher G.; Geitzenauer, Wolfgang; Simader, Christian; Gregori, Giovanni; Schmidt-Erfurth, Ursula.

In: Investigative Ophthalmology and Visual Science, Vol. 50, No. 5, 01.12.2009, p. 2376-2383.

Research output: Contribution to journalArticle

@article{07db1a5a303d4369bccbd4ad720f120e,
title = "Evaluation of ranibizumab-induced changes in high- resolution optical coherence tomographic retinal morphology and their impact on visual function",
abstract = "PURPOSE. To evaluate the effects of intravitreal ranibizumab on retinal function and morphology and to identify a correlation between anatomy and function by using spectral domain optical coherence tomography (SDOCT). METHODS. Twenty-three patients affected by neovascular AMD received three injections of ranibizumab in three consecutive months and were monitored by assessment of best corrected visual acuity (BCVA), central retinal sensitivity (CRS) and morphologic changes at the level of the retina and the retinal pigment epithelium (RPE). The morphologic changes, identified by SDOCT segmentation, were mean retinal thickness (MRT), central retinal thickness (CRT), and the pathologic area (lesion area) of the RPE. RESULTS. BCVA increased from a mean 60.1 ± 8.7 letters at baseline to 67.0 ± 10.9 at month 3 (P = 0.0003). The CRS at the 0° position increased from 2.8 ± 3.1 dB at baseline to 4.0 ± 5.7 at week 1, remaining stable until month 3. Absolute scotoma size decreased continuously from baseline to month 3, in a mean of 5.3 ± 5.8 to 3.6 ± 4.0 test point locations. By SDOCT, MRT decreased from 308.6 ± 25.9 m at baseline to 268.4 ± 22.4 m at month 3 (P = 0.0001). CRT was 365.8 ± 84.9 and 254.9 ± 95.1 μm at month 3 (P = 0.0002). The mean RPE lesion area was 6.0 ± 3.0 mm2 at baseline, which decreased to 5.0 ± 3.1 mm2 at month 3 (P = 0.115). The only significant correlation was identified between the lesion area and CRS. CONCLUSIONS. In ranibizumab therapy, the condition of the RPE lesion may be more relevant for visual function than the usual OCT parameters, retinal thickness.",
author = "Kiss, {Christopher G.} and Wolfgang Geitzenauer and Christian Simader and Giovanni Gregori and Ursula Schmidt-Erfurth",
year = "2009",
month = "12",
day = "1",
doi = "10.1167/iovs.08-2017",
language = "English",
volume = "50",
pages = "2376--2383",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "5",

}

TY - JOUR

T1 - Evaluation of ranibizumab-induced changes in high- resolution optical coherence tomographic retinal morphology and their impact on visual function

AU - Kiss, Christopher G.

AU - Geitzenauer, Wolfgang

AU - Simader, Christian

AU - Gregori, Giovanni

AU - Schmidt-Erfurth, Ursula

PY - 2009/12/1

Y1 - 2009/12/1

N2 - PURPOSE. To evaluate the effects of intravitreal ranibizumab on retinal function and morphology and to identify a correlation between anatomy and function by using spectral domain optical coherence tomography (SDOCT). METHODS. Twenty-three patients affected by neovascular AMD received three injections of ranibizumab in three consecutive months and were monitored by assessment of best corrected visual acuity (BCVA), central retinal sensitivity (CRS) and morphologic changes at the level of the retina and the retinal pigment epithelium (RPE). The morphologic changes, identified by SDOCT segmentation, were mean retinal thickness (MRT), central retinal thickness (CRT), and the pathologic area (lesion area) of the RPE. RESULTS. BCVA increased from a mean 60.1 ± 8.7 letters at baseline to 67.0 ± 10.9 at month 3 (P = 0.0003). The CRS at the 0° position increased from 2.8 ± 3.1 dB at baseline to 4.0 ± 5.7 at week 1, remaining stable until month 3. Absolute scotoma size decreased continuously from baseline to month 3, in a mean of 5.3 ± 5.8 to 3.6 ± 4.0 test point locations. By SDOCT, MRT decreased from 308.6 ± 25.9 m at baseline to 268.4 ± 22.4 m at month 3 (P = 0.0001). CRT was 365.8 ± 84.9 and 254.9 ± 95.1 μm at month 3 (P = 0.0002). The mean RPE lesion area was 6.0 ± 3.0 mm2 at baseline, which decreased to 5.0 ± 3.1 mm2 at month 3 (P = 0.115). The only significant correlation was identified between the lesion area and CRS. CONCLUSIONS. In ranibizumab therapy, the condition of the RPE lesion may be more relevant for visual function than the usual OCT parameters, retinal thickness.

AB - PURPOSE. To evaluate the effects of intravitreal ranibizumab on retinal function and morphology and to identify a correlation between anatomy and function by using spectral domain optical coherence tomography (SDOCT). METHODS. Twenty-three patients affected by neovascular AMD received three injections of ranibizumab in three consecutive months and were monitored by assessment of best corrected visual acuity (BCVA), central retinal sensitivity (CRS) and morphologic changes at the level of the retina and the retinal pigment epithelium (RPE). The morphologic changes, identified by SDOCT segmentation, were mean retinal thickness (MRT), central retinal thickness (CRT), and the pathologic area (lesion area) of the RPE. RESULTS. BCVA increased from a mean 60.1 ± 8.7 letters at baseline to 67.0 ± 10.9 at month 3 (P = 0.0003). The CRS at the 0° position increased from 2.8 ± 3.1 dB at baseline to 4.0 ± 5.7 at week 1, remaining stable until month 3. Absolute scotoma size decreased continuously from baseline to month 3, in a mean of 5.3 ± 5.8 to 3.6 ± 4.0 test point locations. By SDOCT, MRT decreased from 308.6 ± 25.9 m at baseline to 268.4 ± 22.4 m at month 3 (P = 0.0001). CRT was 365.8 ± 84.9 and 254.9 ± 95.1 μm at month 3 (P = 0.0002). The mean RPE lesion area was 6.0 ± 3.0 mm2 at baseline, which decreased to 5.0 ± 3.1 mm2 at month 3 (P = 0.115). The only significant correlation was identified between the lesion area and CRS. CONCLUSIONS. In ranibizumab therapy, the condition of the RPE lesion may be more relevant for visual function than the usual OCT parameters, retinal thickness.

UR - http://www.scopus.com/inward/record.url?scp=65549147695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549147695&partnerID=8YFLogxK

U2 - 10.1167/iovs.08-2017

DO - 10.1167/iovs.08-2017

M3 - Article

C2 - 19136707

AN - SCOPUS:65549147695

VL - 50

SP - 2376

EP - 2383

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 5

ER -